3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
46
Neoplasms
5
Neoplasm Metastasis
5
Metastatic Castration-Resistant Prostate Cancer
3
Adenocarcinoma
3
Recurrence
2
Prostatic Neoplasms, Castration-Resistant
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer
2
Bulbo-Spinal Atrophy, X-Linked
2
mCRPC
1
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sleep Initiation and Maintenance Disorders
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
NSCLC Harboring NRG1 Fusion
1
Metastatic Hormone Sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Lymphoma, Follicular
1
Fatigue
1
Depression
1
Colorectal Neoplasms
1
Castration Resistant Metastatic Prostate Cancer
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
fludarabine
2
durvalumab
2
Cyclophosphamide
2
ruxolitinib
1
repotrectinib
1
ponatinib
1
pembrolizumab
1
gilteritinib
1
fludarabine phosphate
1
cemiplimab
1
atezolizumab
1
Whole-Body Irradiation
1
Tacrolimus
1
Peripheral Blood Stem Cell Transplantation
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Nivolumab
1
Mycophenolic Acid
1
Mesna
1
Melphalan
1
Immunotherapy
1
Idarubicin
1
Granulocyte Colony-Stimulating Factor
1
Docetaxel
1
Cytarabine
1
Cisplatin
1
CPI-0610
1
Busulfan
1
Bone Marrow Transplantation
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
enzalutamide
×
90 days
×
Clear all
No trials found.